Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 28, 2015 5:08 PM ET

Life Sciences Tools and Services

Company Overview of Progenitor Cell Therapy, LLC

Company Overview

Progenitor Cell Therapy, LLC provides contract development and manufacturing services for cell therapy products. The company offers manufacturing solutions; engineering and innovation services; product and process development services; cell and tissue processing; storage, distribution, and delivery of tissues, primary cells, and cell therapy products; and consulting and regulatory support services, such as product and process development, GTP/cGMP manufacturing, regulatory services, and business development and commercialization. It serves academic, biotech, pharmaceutical, and professional clients in the United States. The company was founded in 1997 and is based in Allendale, New Jersey. I...

4 Pearl Court

Suite C

Allendale, NJ 07401

United States

Founded in 1997





Key Executives for Progenitor Cell Therapy, LLC

President, Chief Scientific Officer and Member of Board Manager
Age: 58
Chief Medical Officer
Age: 58
Senior Vice President of Investor Relations
Director of Human Resources
Vice President of Business Development
Compensation as of Fiscal Year 2015.

Progenitor Cell Therapy, LLC Key Developments

PCT, LLC to Expand its Current Manufacturing Capacity at Allendale, New Jersey Facility to Support IRX Therapeutics

PCT, LLC announced that it will expand its current manufacturing capacity at PCT's Allendale, New Jersey facility to support IRX Therapeutics Inc.'s anticipated clinical trial manufacturing needs for the INSPIRE Phase 2b study in head and neck cancer patients. PCT will provide IRX with personnel and dedicated clean room capacity within its current Good Manufacturing Practices (cGMP) infrastructure and, subsequently, pursuant to European Union (EU) cell therapy manufacturing standards. The expanded arrangement includes IRX's use of PCT's ISO Class 6/Class 1,000 clean room system, enabling manufacture of cell-based products that can then be shipped to Europe and, when approved, commercially distributed on the EU market.

Trakcel Ltd. Announce Collaboration Agreement with Caladrius Biosciences, Inc. and its Subsidiary PCT to Drive Cell Therapy Manufacturing Excellence

TrakCel Ltd. announced a collaboration agreement with Caladrius Biosciences, Inc. and its subsidiary PCT, a Caladrius Company to implement its cell therapy process management and supply chain integration technology. TrakCel’s technology integrates and automates the entire cell therapy process end-to-end while providing real-time audit logs and chain-of-custody records to stakeholders. It further reduces the implementation risks associated with disparate, paper-based systems as TrakCel technology accelerates scale up and scale out of cell therapy processes through immediate access to data for validation and regulatory audits. PCT and TrakCel will undertake in fourth quarter of 2015 a design specification stage prior to implementing a customized cell therapy process management solution based on TrakCel’s technology. PCT has full-scale cGMP/GLP operations in New Jersey and California, thousands of square feet of Class 10,000 clean rooms, and full QA/QC support. The company has had over 100 clients whose products have treated over 6,000 patients. The collaboration agreement supports UK-based TrakCel’s strategy to expand into the US market, and comes ahead of the company’s plan to establish US offices in 2015.

ImmunoCellular Therapeutics Selects PCT, LLC to Manufacture ICT-107 Immunotherapy for Glioblastoma

Caladrius Biosciences (CLBS) announced that its subsidiary, PCT, LLC, has been selected by ImmunoCellular Therapeutics (IMUC) as the US manufacturer for ImmunoCellular's ICT-107 phase 3 registrational clinical program in newly diagnosed glioblastoma, anticipated to begin in the second half of 2015. Under the terms of the multi-year agreement, PCT will provide current good manufacturing practice (cGMP) services for the manufacture of clinical supplies of ICT-107, a dendritic cell-based immunotherapy targeting six tumor-associated antigens.

Similar Private Companies By Industry

Company Name Region
Kestrel Consultants, Inc. United States
Sterigenics Holdings, Inc. United States
WaveSense, Inc. United States
Lonza Houston, Inc. United States
Transposagen Biopharmaceuticals, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Progenitor Cell Therapy, LLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at